DOCSLIB.ORG

Mechanisms of Extracellular Nucleotide Accumulation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mechanisms of Extracellular Nucleotide Accumulation MECHANISMS OF EXTRACELLULAR NUCLEOTIDE ACCUMULATION DURING REGULATED CELL DEATH IN TUMOR CELLS By ANDREA MICHELLE BOYD TRESSLER Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: George R Dubyak, PhD Department of Pharmacology Case Western Reserve University May 2016 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of Andrea Michelle Boyd Tressler candidate for the degree of Doctor of Philosophy*. Ruth Keri (Committee Chair) George Dubyak (Dissertation Advisor) Vera Moiseenkova-Bell (Committee Member) Clark Distelhorst (Committee Member) Thomas Kelley (Committee Member) Date of Defense March 22, 2016 *We also certify that written approval has been obtained for any proprietary material contained therein. i Dedication I would like to dedicate this to my parents, Nik and Debbie, who have been my biggest supporters my entire life. From ballet lessons to my PhD, they have always challenged and encouraged me, sacrificing time and money to make sure they were front and center at everything I did. I would not be the woman I am today without them. Also, to my niece, Taylor, who is my favorite person and a big reason I’ve never given up. ii Table of Contents List of Figures ………………….……………………..…………...…………….......vi Acknowledgements …………………………………………………………………x List of Abbreviations………………………………………………………………...xii Abstract………………………………………………………………………………….1 Chapter 1: Introduction and Background…………………………………………3 1.1 Tumor immunotherapy………………….………………………………………….3 1.2 Programmed Cell Death………………….………………………………………..8 1.2.1 Apoptosis………………………………………………………………………….8 1.2.1.1 Extrinsic…………………………………………………….……………………8 1.2.1.2 Intrinsic…………………………………………………………………………12 1.2.2 Necroptosis………………………………………………………………………13 1.3 Chemotherapeutic Drugs…………………………………………..………….....18 1.3.1 Doxorubicin……………………………………...…………………..…………..18 1.3.2 Etoposide……………………………………………………………..………….19 1.3.3 Staurosporine…………………………………………………………..………..20 1.4 Release of Intracellular ATP…………………………………………….……….21 1.4.1 Purinergic Signaling…………………………………………………….………21 1.4.2 Mechanisms of ATP Release…………………………………………..……...22 1.4.2.1 Exocytosis …………………………………………………………………….23 1.4.2.2 Plasma Membrane Permeabilization……………………………………….23 1.4.2.3 Regulated efflux via channels……………………………………………….23 iii 1.5 Pannexin 1 Channel……………………………………………………………....26 1.6 ATP metabolism…………………………………………………………………...31 1.6.1 Ecto-Nucleotide triphosphate diphosphohydrolase………………………...32 1.6.2 Ecto-nucleotide pyrophosphatase/phosphodiesterase…………………….32 1.6.3 CD73……………………………………………………………………………..32 1.7 Statement of Purpose…………………………………………………………….33 Chapter 2: Materials and Methods………………………………………………...36 Chapter 3: Chemotherapeutic Drugs Induce ATP Release via Caspase- gated Pannexin-1 Channels and a Caspase/Pannexin-1-independent Mechanism………………………………………………………………………….....47 3.1 Abstract…………………………………………………………………………….47 3.2 Introduction………………………………………………………………………..48 3.3 Results……………………………………………………………………………..51 3.4 Discussion………………………………………………………………………....67 3.5 Acknowledgements……………………………………………………………….77 Chapter 4: Upregulated ectonucleotidases in FADD- and RIP1-deficient Jurkat leukemia cells counteracts extracellular ATP/AMP accumulation via pannexin-1 channels during chemotherapeutic drug-induced apoptosis ...…………………..……………...........................................................................101 4.1 Abstract…………………………………………………………………………...101 4.2 Introduction……………………………………………………………………....102 4.3 Results………………………………………………………………………..…..106 4.5 Discussion…………………………………………………………………..……121 iv 4.5 Acknowledgements……………………………………………………………...130 Chapter 5: Regulation of Adenine Nucleotide release through Pannexin 1 channels in EG7 Murine Lymphoma Cells…………………………………......147 Chapter 6: Discussion and Future Directions……………………………..…..157 6.1 Mechanisms of Programmed Cell Death Induced Adenine Nucleotide Release……………………………………………………………………..………...159 6.2 Role of FADD and RIP1 in ectonucleotidase activity……………..………….160 6.3 Decrease in immune cell activation………………………………..…………..163 6.4 Post-translational modification of Panx1………………………………………164 6.5 Concluding Remarks…………………………………………………………….166 Appendix……………………………………………………………………………..170 References………………………………………………………………………...…185 v List of Figures Figure 1.1: Activation of the purinergic anti-tumor immune response after treatment of chemotherapy………………………………………………………..…...5 Figure 1.2: Intrinsic and Extrinsic Activation of Apoptosis…………………….........9 Figure 1.3: TNF signaling……………………………………………………………..15 Figure 1.4: Mechanisms of ATP Release…………………………………………...24 Figure 1.5: Pannexin 1 Channel……………………………………………………..27 Figure 3.1: Comparative time courses for accumulation of active caspase-3 and loss of viability in Jurkat leukemic T cells treated with different chemotherapeutic agents…………………………………………………………………………………..78 Figure 3.2: Chemotherapeutic drugs induce caspase-3 mediated cleavage of the pannexin-1 C-terminal autoinhibitory domain………………………………………80 Figure 3.3: Chemotherapeutic drugs induce accumulation of active pannexin-1 channels via a caspase dependent activation mechanism………………………..82 Figure 3.4: Efflux of both ATP and ATP metabolites is triggered during chemotherapeutic drug-induced apoptosis of Jurkat cells………………………...84 Figure 3.5: Caspase-activated pannexin-1 channels mediate the efflux of ATP and ATP metabolites during chemotherapeutic drug-induced apoptosis but an alternative ATP release mechanism is engaged in the context of suppressed caspase activity………………………………………………………………………..87 Figure 3.6: Carbenoxolone blocks the efflux of ATP and ATP metabolites during chemotherapeutic drug-induced apoptosis…………………………………………89 vi Figure 3.7: Caspase-insensitive ATP release stimulated by chemotherapeutic drugs is resistant to carbenoxolone blockade but suppressed by intracellular Ca2+ buffering………………………………………………………………………….91 Figure 3.8: Caspase-insensitive ATP release stimulated by staurosporine does not involve direct Ca2+mobilization by staurosporine or activation of phosphatidyl inositol phospholipase C signaling…………………………………………………..94 Figure 3.9: Proteosome inhibition induces caspase-3-mediated cleavage of the pannexin-1 C-terminal autoinhibitory domain and pannexin-1-mediated release of adenine nucleotides…………………………………………………………………...96 Figure 3.10: Pannexin-1 is more highly expressed in human leukemic leukocytes than in normal human T cells…………………………………………………………99 Figure 4.1: TNFα-induction of necroptosis or extrinsic apoptosis induces release of adenine nucleotides from Jurkat cancer cells via mechanistically distinct pathways………………………………………………………………………..…….131 Figure 4.2: Intrinsic apoptotic signaling and Panx1 channel cleavage in FADD- deficient Jurkat cancer cells is uncoupled from accumulation of extracellular adenine nucleotides………………………………………………………………….134 Figure 4.3: Caspase-3-cleaved Panx1 channels are functionally active in FADD- deficient Jurkat cancer cells during intrinsic apoptosis………………………......136 Figure 4.4: CD73 ecto-nucleotidase activity is upregulated in FADD-deficient Jurkat cancer cells and counteracts Panx1 channel-mediated efflux of ATP/AMP during intrinsic apopotosis…………………………………………………………..138 vii Figure 4.5: Apoptotic signaling and Panx1 channel activation in RIP1-deficient Jurkat cancer cells is also uncoupled from accumulation of extracellular adenine nucleotides……………………………………………………………………………140 Figure 4.6: RIP1 deficient cells have increased CD73 activity………………….143 Figure 4.7: Increased expression of CD39 ecto-ATPase in RIP1-deficient Jurkat cells relative to FADD-deficient or wildtype Jurkat cells………………………….145 Figure 5.1: Comparative activation of apoptosis in Jurkat T cells and EG7 cells treated with chemotherapeutic agent ……..……………………………………….151 Figure 5.2: Activation of apoptosis in EG7 cells by chemotherapies does not lead to Panx1 mediated Adenine Nucleotide accumulation…………………………..153 Figure 5.3: Cleavage of Panx1 in EG7 cells leads to increased YO-Pro dye influx…………………………………………………………………………………...155 Appendix 1: Full Western Blot of Panx1 in Anti-Fas-treated Jurkat T cells in the presence of absence of zVAD………………………………………………………170 Appendix 2: Full Western Blot of Panx1 in STS-treated Jurkat T cells in the presence of absence of zVAD………………………………………………………171 Appendix 3: Full Western Blot of Panx1 in Dox-treated Jurkat T cells in the presence of absence of zVAD………………………………………………………172 Appendix 4: Full Western Blot of Panx1 in Etop-treated Jurkat T cells in the presence of absence of zVAD………………………………………………………173 Appendix 5: Full Western Blot of Panx1 in TS- or Anti-Fas-treated WT Jurkat T cells…………………………………………………………………………………….174 viii Appendix 6: Full Western Blot of Panx1 in TS- or TS+zVAD-treated FADD-def Jurkat T cells………………………………………………………………………….175 Appendix 7: Full Western Blot of Panx1 in STS-, Etop- or Anti-Fas-treated WT Jurkat T cells………………………………………………………………………….176 Appendix 8: Full Western Blot of Panx1 in STS-, Etop- or Anti-Fas-treated FADD- def Jurkat T cells……………………………………………………………………..177 Appendix 9: Full Western Blot of Panx1 in STS-, or Etop-treated WT and RIP1- def Jurkat T cells…………………………………………………………………….178 Appendix 10: Full Western Blot of Panx1 in STS- or Dox-treated EG7 Lymphoma cells…………………………………………………………………………………….179 Appendix 11: Copy right permission forms………………………………………..180 ix Acknowledgements I would first like to thank my advisor, Dr. George Dubyak for giving me the amazing opportunity to work in his lab. When I
Load more

Recommended publications
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
    [Show full text]
  • Immuno-Oncology Panel 1
    Immuno-Oncology panel 1 Gene Symbol Target protein name UniProt ID (& link) Modification* (56 analytes) ADA17 ADAM17 metalloprotease domain 17 P78536 *blanks mean the assay detects the ANXA1 Annexin A1 P04083 non-modified peptide sequence ANXA1 Annexin A1 P04083 ARG2 arginase, type II P78540 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS2996 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 pS367 ATM Serine-protein kinase ATM, Ataxia telangiectasia mutated Q13315 C10orf54 / VISTA chromosome 10 open reading frame 54 Q9H7M9 CCL5 C-C motif chemokine ligand 5 P13501 CD14 CD14 molecule P08571 CD163 CD163 molecule Q86VB7 CD274 / PDL1 Programmed cell death 1 ligand 1 CD274 Q9NZQ7 CD33 CD33 molecule P20138 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD40/TNR5 tumor necrosis factor receptor superfamily member 5 P25942 CD47 CD47 molecule Q08722 CD70 CD70 antigen P32970 CD74/HG2A CD74 molecule, major histocompatibility complex, class II invariant chain Q8SNA0 CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8 P31997 CX3CL1 C-X3-C motif chemokine ligand 1 P78423 CXCL10 C-X-C motif chemokine ligand 10 P02778 CXCL13 chemokine (C-X-C motif) ligand 13 O43927 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 Q86VV3 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 pY291 FAS/TNR6 Fas (TNF receptor superfamily, member 6) P25445 GAPDH Glyceraldehyde-3-phosphate dehydrogenase P04406 HAVCR2 hepatitis
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Propranolol-Mediated Attenuation of MMP-9 Excretion in Infants with Hemangiomas
    Supplementary Online Content Thaivalappil S, Bauman N, Saieg A, Movius E, Brown KJ, Preciado D. Propranolol-mediated attenuation of MMP-9 excretion in infants with hemangiomas. JAMA Otolaryngol Head Neck Surg. doi:10.1001/jamaoto.2013.4773 eTable. List of All of the Proteins Identified by Proteomics This supplementary material has been provided by the authors to give readers additional information about their work. © 2013 American Medical Association. All rights reserved. Downloaded From: https://jamanetwork.com/ on 10/01/2021 eTable. List of All of the Proteins Identified by Proteomics Protein Name Prop 12 mo/4 Pred 12 mo/4 Δ Prop to Pred mo mo Myeloperoxidase OS=Homo sapiens GN=MPO 26.00 143.00 ‐117.00 Lactotransferrin OS=Homo sapiens GN=LTF 114.00 205.50 ‐91.50 Matrix metalloproteinase‐9 OS=Homo sapiens GN=MMP9 5.00 36.00 ‐31.00 Neutrophil elastase OS=Homo sapiens GN=ELANE 24.00 48.00 ‐24.00 Bleomycin hydrolase OS=Homo sapiens GN=BLMH 3.00 25.00 ‐22.00 CAP7_HUMAN Azurocidin OS=Homo sapiens GN=AZU1 PE=1 SV=3 4.00 26.00 ‐22.00 S10A8_HUMAN Protein S100‐A8 OS=Homo sapiens GN=S100A8 PE=1 14.67 30.50 ‐15.83 SV=1 IL1F9_HUMAN Interleukin‐1 family member 9 OS=Homo sapiens 1.00 15.00 ‐14.00 GN=IL1F9 PE=1 SV=1 MUC5B_HUMAN Mucin‐5B OS=Homo sapiens GN=MUC5B PE=1 SV=3 2.00 14.00 ‐12.00 MUC4_HUMAN Mucin‐4 OS=Homo sapiens GN=MUC4 PE=1 SV=3 1.00 12.00 ‐11.00 HRG_HUMAN Histidine‐rich glycoprotein OS=Homo sapiens GN=HRG 1.00 12.00 ‐11.00 PE=1 SV=1 TKT_HUMAN Transketolase OS=Homo sapiens GN=TKT PE=1 SV=3 17.00 28.00 ‐11.00 CATG_HUMAN Cathepsin G OS=Homo
    [Show full text]
  • CD226 T Cells Expressing the Receptors TIGIT and Divergent Phenotypes of Human Regulatory
    The Journal of Immunology Divergent Phenotypes of Human Regulatory T Cells Expressing the Receptors TIGIT and CD226 Christopher A. Fuhrman,*,1 Wen-I Yeh,*,1 Howard R. Seay,* Priya Saikumar Lakshmi,* Gaurav Chopra,† Lin Zhang,* Daniel J. Perry,* Stephanie A. McClymont,† Mahesh Yadav,† Maria-Cecilia Lopez,‡ Henry V. Baker,‡ Ying Zhang,x Yizheng Li,{ Maryann Whitley,{ David von Schack,x Mark A. Atkinson,* Jeffrey A. Bluestone,‡ and Todd M. Brusko* Regulatory T cells (Tregs) play a central role in counteracting inflammation and autoimmunity. A more complete understanding of cellular heterogeneity and the potential for lineage plasticity in human Treg subsets may identify markers of disease pathogenesis and facilitate the development of optimized cellular therapeutics. To better elucidate human Treg subsets, we conducted direct transcriptional profiling of CD4+FOXP3+Helios+ thymic-derived Tregs and CD4+FOXP3+Helios2 T cells, followed by comparison with CD4+FOXP32Helios2 T conventional cells. These analyses revealed that the coinhibitory receptor T cell Ig and ITIM domain (TIGIT) was highly expressed on thymic-derived Tregs. TIGIT and the costimulatory factor CD226 bind the common ligand CD155. Thus, we analyzed the cellular distribution and suppressive activity of isolated subsets of CD4+CD25+CD127lo/2 T cells expressing CD226 and/or TIGIT. We observed TIGIT is highly expressed and upregulated on Tregs after activation and in vitro expansion, and is associated with lineage stability and suppressive capacity. Conversely, the CD226+TIGIT2 population was associated with reduced Treg purity and suppressive capacity after expansion, along with a marked increase in IL-10 and effector cytokine production. These studies provide additional markers to delineate functionally distinct Treg subsets that may help direct cellular therapies and provide important phenotypic markers for assessing the role of Tregs in health and disease.
    [Show full text]
  • Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule
    Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule Antonella Chillemi,1 Gianluca Zaccarello,1 Valeria Quarona,1 Manuela Ferracin,3 Chiara Ghimenti,4 Massimo Massaia,2,5 Alberto L Horenstein,1,2 and Fabio Malavasi1,2,6 1Laboratory of Immunogenetics, Department of Medical Sciences and 2Research Center on Experimental Medicine (CeRMS), University of Torino Medical School, Torino, Italy; 3Laboratory for Technologies of Advanced Therapies (LTTA) and Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy; 4Cancer Genomics Laboratory, Edo ed Elvo Tempia Foundation, Biella, Italy; 5Laboratory of Hematological Oncology, Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy; and 6Transplantation Immunology Service, Città della Salute e della Scienza Hospital, Torino, Italy In vivo use of monoclonal antibodies (mAbs) has become a mainstay of routine clinical practice in the treatment of various human diseases. A number of molecules can serve as targets, according to the condition being treated. Now entering human clinical trials, CD38 molecule is a particularly attractive target because of its peculiar pattern of expression and its twin role as re- ceptor and ectoenzyme. This review provides a range of analytical perspectives on the current progress in and challenges to anti- CD38 mAb therapy. We present a synopsis of the evidence available on CD38, particularly in myeloma and chronic lymphocytic leukemia (CLL). Our aim is to make the data from basic science helpful and accessible to a diverse clinical audience and, at the same time, to improve its potential for in vivo use. The topics covered include tissue distribution and signal implementation by mAb ligation and the possibility of increasing cell density on target cells by exploiting information about the molecule’s regulation in combination with drugs approved for in vivo use.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • Supplementary Table S2
    1-high in cerebrotropic Gene P-value patients Definition BCHE 2.00E-04 1 Butyrylcholinesterase PLCB2 2.00E-04 -1 Phospholipase C, beta 2 SF3B1 2.00E-04 -1 Splicing factor 3b, subunit 1 BCHE 0.00022 1 Butyrylcholinesterase ZNF721 0.00028 -1 Zinc finger protein 721 GNAI1 0.00044 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 GNAI1 0.00049 1 Guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 1 PDE1B 0.00069 -1 Phosphodiesterase 1B, calmodulin-dependent MCOLN2 0.00085 -1 Mucolipin 2 PGCP 0.00116 1 Plasma glutamate carboxypeptidase TMX4 0.00116 1 Thioredoxin-related transmembrane protein 4 C10orf11 0.00142 1 Chromosome 10 open reading frame 11 TRIM14 0.00156 -1 Tripartite motif-containing 14 APOBEC3D 0.00173 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D ANXA6 0.00185 -1 Annexin A6 NOS3 0.00209 -1 Nitric oxide synthase 3 SELI 0.00209 -1 Selenoprotein I NYNRIN 0.0023 -1 NYN domain and retroviral integrase containing ANKFY1 0.00253 -1 Ankyrin repeat and FYVE domain containing 1 APOBEC3F 0.00278 -1 Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3F EBI2 0.00278 -1 Epstein-Barr virus induced gene 2 ETHE1 0.00278 1 Ethylmalonic encephalopathy 1 PDE7A 0.00278 -1 Phosphodiesterase 7A HLA-DOA 0.00305 -1 Major histocompatibility complex, class II, DO alpha SOX13 0.00305 1 SRY (sex determining region Y)-box 13 ABHD2 3.34E-03 1 Abhydrolase domain containing 2 MOCS2 0.00334 1 Molybdenum cofactor synthesis 2 TTLL6 0.00365 -1 Tubulin tyrosine ligase-like family, member 6 SHANK3 0.00394 -1 SH3 and multiple ankyrin repeat domains 3 ADCY4 0.004 -1 Adenylate cyclase 4 CD3D 0.004 -1 CD3d molecule, delta (CD3-TCR complex) (CD3D), transcript variant 1, mRNA.
    [Show full text]
  • Functional ENTPD1 Polymorphisms in African Americans with Diabetes and End-Stage Renal Disease
    Functional ENTPD1 Polymorphisms in African Americans With Diabetes and End-Stage Renal Disease The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Friedman, David J., Matthew E. Talbert, Donald W. Bowden, Barry I. Freedman, Yves Mukanya, Keiichi Enjyoji, and Simon C. Robson. 2009. Functional ENTPD1 polymorphisms in African Americans With diabetes and end-stage renal disease. Diabetes 58(4): 999-1006. Published Version doi://10.2337/db08-1214 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:5346717 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA ORIGINAL ARTICLE Functional ENTPD1 Polymorphisms in African Americans With Diabetes and End-Stage Renal Disease David J. Friedman,1,2 Matthew E. Talbert,3,4 Donald W. Bowden,3,5,6 Barry I. Freedman,5 Yves Mukanya,7,8 Keiichi Enjyoji,7,8 and Simon C. Robson7,8 OBJECTIVE—The vascular ectonucleotidase ENTPD1 protects against renal injury and modulates glucose homeostasis in mouse models. We sought to determine whether human variation in iabetes and its complications are enormous ENTPD1 influences predisposition to diabetes or diabetic sources of mortality, morbidity, and cost in the nephropathy. U.S. African Americans are especially prone to diabetes and diabetic kidney disease (1). Ge- RESEARCH DESIGN AND METHODS—We analyzed ENTPD1 D single nucleotide polymorphisms (SNPs) in 363 African American netic variation plays a major role in susceptibility to both control subjects, 380 subjects with type 2 diabetes and end-stage development of diabetes and onset of diabetic renal injury renal disease (DM-ESRD), and 326 subjects with ESRD unrelated to (2,3).
    [Show full text]
  • Bioinformatics Analysis for the Identification of Differentially Expressed Genes and Related Signaling Pathways in H
    Bioinformatics analysis for the identification of differentially expressed genes and related signaling pathways in H. pylori-CagA transfected gastric cancer cells Dingyu Chen*, Chao Li, Yan Zhao, Jianjiang Zhou, Qinrong Wang and Yuan Xie* Key Laboratory of Endemic and Ethnic Diseases , Ministry of Education, Guizhou Medical University, Guiyang, China * These authors contributed equally to this work. ABSTRACT Aim. Helicobacter pylori cytotoxin-associated protein A (CagA) is an important vir- ulence factor known to induce gastric cancer development. However, the cause and the underlying molecular events of CagA induction remain unclear. Here, we applied integrated bioinformatics to identify the key genes involved in the process of CagA- induced gastric epithelial cell inflammation and can ceration to comprehend the potential molecular mechanisms involved. Materials and Methods. AGS cells were transected with pcDNA3.1 and pcDNA3.1::CagA for 24 h. The transfected cells were subjected to transcriptome sequencing to obtain the expressed genes. Differentially expressed genes (DEG) with adjusted P value < 0.05, | logFC |> 2 were screened, and the R package was applied for gene ontology (GO) enrichment and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. The differential gene protein–protein interaction (PPI) network was constructed using the STRING Cytoscape application, which conducted visual analysis to create the key function networks and identify the key genes. Next, the Submitted 20 August 2020 Kaplan–Meier plotter survival analysis tool was employed to analyze the survival of the Accepted 11 March 2021 key genes derived from the PPI network. Further analysis of the key gene expressions Published 15 April 2021 in gastric cancer and normal tissues were performed based on The Cancer Genome Corresponding author Atlas (TCGA) database and RT-qPCR verification.
    [Show full text]
  • CD73 Promotes Anthracycline Resistance and Poor Prognosis in Triple Negative Breast Cancer
    CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer Sherene Loia,1, Sandra Pommeyb,1, Benjamin Haibe-Kainsc, Paul A. Beavisd, Phillip K. Darcyd,e, Mark J. Smythd,e,f,g,2, and John Staggb,2,3 aDivision of Cancer Medicine and Research, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia; bFaculté de Pharmacie et Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada H2L 4M1; cBioinformatics and Computational Genomics Laboratory, Institut de Recherches Cliniques de Montréal, Montreal, Canada H2W 1R7; dCancer Immunology Program, Trescowthick Laboratories, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia; eSir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, VIC 3010, Australia; fImmmunology in Cancer and Infection Laboratory, Queensland Institute of Medical Research, Herston, QLD 4006, Australia; and gSchool of Medicine, University of Queensland, Herston, QLD 4006, Australia Edited by Thierry Boon, Ludwig Institute for Cancer Research, Brussels, Belgium, and approved May 23, 2013 (received for review December 30, 2012) Using gene-expression data from over 6,000 breast cancer patients, autophagy (8). Extracellular ATP activates P2X7 receptors on we report herein that high CD73 expression is associated with a poor dendritic cells, which initiates a cascade of events that ultimately + prognosis in triple-negative breast cancers (TNBC). Because anthra- culminates in the generation of IFN-γ–producing CD8 T cells. cycline-based chemotherapy regimens are standard treatment for Because of its proinflammatory effects, extracellular levels of ATP TNBC, we investigated the relationship between CD73 and anthra- are tightly regulated.
    [Show full text]
  • Single-Cell RNA Sequencing Reveals Distinct Cellular Factors for Response
    Open access Original research Single- cell RNA sequencing reveals J Immunother Cancer: first published as 10.1136/jitc-2021-002503 on 12 July 2021. Downloaded from distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer Miok Kim,1 Yong Ki Min,1 Jinho Jang,2,3 Hyejin Park,1 Semin Lee,2,3 1 Chang Hoon Lee To cite: Kim M, Min YK, ABSTRACTS BACKGROUND Jang J, et al. Single- cell RNA Background Although cancer immunotherapy is one of Cancer immunotherapy has generated sequencing reveals distinct the most effective advanced- stage cancer therapies, no cellular factors for response to unparalleled and durable responses in clinically approved cancer immunotherapies currently exist immunotherapy targeting CD73 regard to several cancers and is a pillar of for colorectal cancer (CRC). Recently, programmed cell death 1 and PD-1 in colorectal cancer. advanced-stage cancer therapy. Colorectal protein 1 (PD-1) blockade has exhibited clinical benefits Journal for ImmunoTherapy cancer (CRC) is one of the most prominent of Cancer 2021;9:e002503. according to ongoing clinical trials. However, ongoing clinical causes of cancer- related deaths and exhibits doi:10.1136/jitc-2021-002503 trials for cancer immunotherapies are focused on PD-1 2 signaling inhibitors such as pembrolizumab, nivolumab, and high rates of morbidity and mortality. Recent clinical trials examining the use of immune ► Additional supplemental atezolizumab. In this study, we focused on revealing the material is published online only. distinct response mechanism for the potent CD73 ectoenzyme checkpoint inhibitors (ICIs) are anticipated 3 4 To view, please visit the journal selective inhibitor AB680 as a promising drug candidate that to improve survival rates in CRC.
    [Show full text]